|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **PEG3350+E (n=48)** | | | **PEG4000 (n=49)** | | |  |
|  | Events (n) | Subjects with event (n) | % of subjects | Events (n) | Subjects with event  (n) | % of subjects | p |
| **Gastrointestinal disorders** |  |  |  |  |  |  |  |
| * Abdominal pain | 0 | 0 | 0% | 3 | 3 | 6% | 0.24 |
| * Diarrhoea | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| * Mouth ulceration | 0 | 0 | 0% | 2 | 1 | 2% | 1.00 |
| * Nausea | 3 | 3 | 6% | 2 | 2 | 4% | 0.68 |
| * Toothache | 3 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * Vomiting | 2 | 2 | 4% | 4 | 4 | 8% | 0.68 |
| **General disorders** |  |  |  |  |  |  |  |
| * Influenza like illness | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| * Pyrexia | 4 | 4 | 8% | 9 | 9 | 18% | 0.23 |
| **Infections and infestations** |  |  |  |  |  |  |  |
| * Bronchitis | 2 | 2 | 4% | 0 | 0 | 0% | 0.24 |
| * Ear infection | 2 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| * Eye infection | 2 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * Gastroenteritis | 6 | 5 | 10% | 3 | 2 | 4% | 0.27 |
| * Gastroenteritis viral | 3 | 3 | 6% | 5 | 3 | 6% | 1.00 |
| * Influenza | 1 | 1 | 2% | 3 | 2 | 4% | 1.00 |
| * Nasopharyngitis | 5 | 4 | 8% | 7 | 5 | 10% | 1.00 |
| * Pseudocroup | 2 | 2 | 4% | 0 | 0 | 0% | 0.24 |
| * Respiratory tract infection | 0 | 0 | 0% | 2 | 2 | 4% | 0.49 |
| * Upper respiratory tract infection | 3 | 1 | 2% | 4 | 3 | 6% | 0.62 |
| * Urinary tract infection | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| * Varicella | 3 | 3 | 6% | 1 | 1 | 2% | 0.36 |
| * Viral infection | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| **Metabolism and nutrition disorders** |  |  |  |  |  |  |  |
| * Dehydration | 2 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| **Nervous system disorders** |  |  |  |  |  |  |  |
| * Headache | 1 | 1 | 2% | 5 | 3 | 6% | 0.62 |
| **Renal and urinary disorders** |  |  |  |  |  |  |  |
| * Polyuria | 1 | 1 | 2% | 2 | 1 | 2% | 1.00 |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  |  |  |  |  |
| * Cough | 2 | 1 | 2% | 0 | 0 | 0% | 0.49 |
| * Oropharyngeal pain | 0 | 0 | 0% | 2 | 2 | 4% | 0.49 |
| **Skin and subcutaneous tissue disorders** | 2 | 2 | 4% | 2 | 2 | 4% | 1.00 |
| * Eczema | 1 | 1 | 2% | 1 | 1 | 2% | 1.00 |
| **Total** | 70 | 28 | 58% | 73 | 28 | 57% | 1.00 |

**Suppl Table 3.** All adverse events that occurred at least twice (ITT population).